Chronic Cough — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Cough is a natural defense mechanism that aids airway clearance by addressing secretions, exudates, or foreign bodies. The intricate nervous pathways, comprising afferent, central, and efferent components, play a key role in understanding the diverse mechanisms behind physiological and pathological cough, particularly chronic cough. Chronic cough, especially in adults, is a prevalent symptom necessitating medical attention, often lacking identifiable causes. In children, chronic cough differs in characteristics and is typically associated with identifiable underlying causes. For adults, chronic cough is defined as persisting for more than 8 weeks and is present in 5–10% of the adult population, predominantly among women over 50. These individuals often exhibit a hyper-reactive response to triggers, resulting in a pronounced tickling or irritation in the throat, compelling them to cough. Chronic cough can manifest irregularly, with some experiencing weeks of troublesome cough interspersed with asymptomatic days or weeks. Notably, 40% of adults with chronic cough undergoing specialist evaluation either have no identified cause (unexplained chronic cough) or continue to cough despite optimal treatment for conditions associated with chronic cough (refractory chronic cough). Various factors, such as respiratory infections, air pollutants, occupational irritants, allergens, eosinophils, refluxate, and biological traits like age or sex hormonal status, can sensitize and trigger cough, posing potential risk factors for chronic cough. Cigarette smokers are three times more likely to report chronic cough, primarily due to chronic bronchitis, although the majority of patients in cough specialist clinics are non-smokers. Managing chronic cough is often intricate, especially in patients with multiple comorbidities and when interventions may prove refractory. The approach involves treating underlying conditions contributing to chronic cough and implementing therapies targeting cough hypersensitivity in refractory or unexplained cough cases.
- Chronic cough affects approximately 10% of adults in various general populations.
Thelansis’s “Chronic Cough Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Cough treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Chronic Cough across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Chronic Cough Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
